ArticleJournal for immunotherapy of cancer2020

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.

Taiki Kurino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.